Amalgamated Bank’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $824K | Sell |
33,272
-177
| -0.5% | -$4.22K | 0.01% | 1144 |
|
|
2025
Q4 | $781K | Sell |
33,449
-300
| -0.9% | -$6.68K | 0.01% | 1165 |
|
|
2025
Q3 | $665K | Buy |
33,749
+1,130
| +3% | +$23.2K | ﹤0.01% | 1210 |
|
|
2025
Q2 | $708K | Buy |
32,619
+654
| +2% | +$15.4K | 0.01% | 1166 |
|
|
2025
Q1 | $775K | Sell |
31,965
-885
| -3% | -$19.9K | 0.01% | 1113 |
|
|
2024
Q4 | $686K | Hold |
32,850
| – | – | 0.01% | 1190 |
|
|
2024
Q3 | $653K | Sell |
32,850
-1,406
| -4% | -$26.1K | 0.01% | 1205 |
|
|
2024
Q2 | $531K | Sell |
34,256
-1,088
| -3% | -$16.9K | ﹤0.01% | 1278 |
|
|
2024
Q1 | $563K | Sell |
35,344
-8,105
| -19% | -$122K | ﹤0.01% | 1267 |
|
|
2023
Q4 | $730K | Sell |
43,449
-879
| -2% | -$12K | 0.01% | 1280 |
|
|
2023
Q3 | $518K | Hold |
44,328
| – | – | ﹤0.01% | 1384 |
|
|
2023
Q2 | $596K | Buy |
44,328
+448
| +1% | +$6.45K | ﹤0.01% | 1353 |
|
|
2023
Q1 | $728K | Sell |
43,880
-3,256
| -7% | -$53.7K | 0.01% | 1245 |
|
|
2022
Q4 | $877K | Buy |
47,136
+1,023
| +2% | +$15.8K | 0.01% | 1201 |
|
|
2022
Q3 | $592K | Buy |
46,113
+30,960
| +204% | +$367K | 0.01% | 1350 |
|
|
2022
Q2 | $106K | Buy |
15,153
+3,463
| +30% | +$25.4K | ﹤0.01% | 2146 |
|
|
2022
Q1 | $97K | Sell |
11,690
-953
| -8% | -$6.74K | ﹤0.01% | 2204 |
|
|
2021
Q4 | $86K | Sell |
12,643
-402
| -3% | -$2.64K | ﹤0.01% | 2078 |
|
|
2021
Q3 | $69K | Sell |
13,045
-593
| -4% | -$3.24K | ﹤0.01% | 2111 |
|
|
2021
Q2 | $78K | Sell |
13,638
-1,463
| -10% | -$7.55K | ﹤0.01% | 2132 |
|
|
2021
Q1 | $70K | Hold |
15,101
| – | – | ﹤0.01% | 1567 |
|
|
2020
Q4 | $50K | Buy |
15,101
+90
| +0.6% | +$302 | ﹤0.01% | 1560 |
|
|
2020
Q3 | $45K | Sell |
15,011
-339
| -2% | -$1.33K | ﹤0.01% | 1463 |
|
|
2020
Q2 | $71K | Sell |
15,350
-1,753
| -10% | -$7.88K | ﹤0.01% | 1434 |
|
|
2020
Q1 | $66K | Buy |
17,103
+68
| +0.4% | +$279 | ﹤0.01% | 1540 |
|
|
2019
Q4 | $64K | Hold |
17,035
| – | – | ﹤0.01% | 1774 |
|
|
2019
Q3 | $90K | Sell |
17,035
-113
| -0.7% | -$602 | ﹤0.01% | 1664 |
|
|
2019
Q2 | $66K | Buy |
17,148
+2,059
| +14% | +$8.89K | ﹤0.01% | 1728 |
|
|
2019
Q1 | $77K | Buy |
15,089
+499
| +3% | +$1.47K | ﹤0.01% | 1617 |
|
|
2018
Q4 | $28K | Buy |
+14,590
| New | +$41.8K | ﹤0.01% | 1601 |
|
|
2018
Q3 | – | Sell |
-14,892
| Closed | -$46K | – | 1485 |
|
|
2018
Q2 | $46K | Buy |
14,892
+3,390
| +29% | +$10.3K | ﹤0.01% | 1711 |
|
|
2018
Q1 | $27K | Buy |
+11,502
| New | +$38.2K | ﹤0.01% | 1599 |
|
Other funds holding CPRX
VCM
DM
VPM
Amalgamated Bank's CPRX Position: Q1 2026 in Review
Amalgamated Bank reduced its Catalyst Pharmaceutical (CPRX) stake by 0.53% in Q1 2026, selling an estimated $4.22K and leaving 33,272 shares worth $824K. The position accounts for 0.01% of the portfolio, ranked #1144.
Amalgamated Bank first reported a position in CPRX in Q1 2018 and has held it in 32 quarters since. The position peaked at $877K in Q4 2022. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- Amalgamated Bank held 33,272 shares of Catalyst Pharmaceutical worth $824K as of Q1 2026.
- Amalgamated Bank sold 177 Catalyst Pharmaceutical shares in Q1 2026, an estimated $4.22K.
- Catalyst Pharmaceutical made up 0.01% of Amalgamated Bank's portfolio in Q1 2026, its #1144 holding.
- Amalgamated Bank first reported a position in Catalyst Pharmaceutical in Q1 2018 and has held it in 32 quarters since.
- Amalgamated Bank's Catalyst Pharmaceutical position peaked at $877K in Q4 2022.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.